These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 29121177)

  • 1. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
    Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
    J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.
    Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Basch E; Keating NL
    JAMA Health Forum; 2021 May; 2(5):e210673. PubMed ID: 35977314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.
    Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Wood WA; Olszewski A; Basch E; Keating NL
    J Natl Cancer Inst; 2020 Oct; 112(10):1055-1062. PubMed ID: 31883008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps.
    Yeung K; Barthold D; Dusetzina SB; Basu A
    N Engl J Med; 2020 Aug; 383(6):558-566. PubMed ID: 32757524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Was federal parity associated with changes in Out-of-network mental health care use and spending?
    Busch SH; Mcginty EE; Stuart EA; Huskamp HA; Gibson TB; Goldman HH; Barry CL
    BMC Health Serv Res; 2017 May; 17(1):315. PubMed ID: 28464814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Mental Health Parity and Addiction Equity Act on Specialty Outpatient Behavioral Health Spending and Utilization.
    Gertner AK; Rotter J; Cruden G
    J Ment Health Policy Econ; 2018 Sep; 21(3):91-103. PubMed ID: 30530870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.
    Shih YC; Smieliauskas F; Geynisman DM; Kelly RJ; Smith TJ
    J Clin Oncol; 2015 Jul; 33(19):2190-6. PubMed ID: 25987701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacy benefit spending on oral chemotherapy drugs.
    Curtiss FR
    J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Savings needed to fund health insurance and health care expenses in retirement: findings from a simulation model.
    Fronstin P; Salisbury D; VanDerhei J
    EBRI Issue Brief; 2008 May; (317):1-2, 4-27. PubMed ID: 18630312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
    Kircher SM; Meeker CR; Nimeiri H; Geynisman DM; Zafar SY; Shankaran V; de Souza J; Wong YN
    Value Health; 2016 Jan; 19(1):88-98. PubMed ID: 26797241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in mental health insurance benefits and out-of-pocket spending.
    McKusick DR; Mark TL; King EC; Coffey RM; Genuardi J
    J Ment Health Policy Econ; 2002 Jun; 5(2):71-8. PubMed ID: 12529560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Chin AL; Bentley JP; Pollom EL
    Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State variations in the out-of-pocket spending burden for outpatient mental health treatment.
    Zuvekas SH; Meyerhoefer CD
    Health Aff (Millwood); 2009; 28(3):713-22. PubMed ID: 19414879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Outcome Changes in Individuals With Type 1 Diabetes After a State-Level Insulin Copayment Cap.
    Giannouchos TV; Ukert B; Buchmueller T
    JAMA Netw Open; 2024 Aug; 7(8):e2425280. PubMed ID: 39141389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral health insurance parity for federal employees.
    Goldman HH; Frank RG; Burnam MA; Huskamp HA; Ridgely MS; Normand SL; Young AS; Barry CL; Azzone V; Busch AB; Azrin ST; Moran G; Lichtenstein C; Blasinsky M
    N Engl J Med; 2006 Mar; 354(13):1378-86. PubMed ID: 16571881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.